What one share of Fulcrum Therapeutics holds
We are a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need.
Fulcrum Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.21 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.94 |
| Cash and investments | $0.64 |
| Book value | $4.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$31.14 | $7.14 | −$25.09 | — | −$40.10 |
| 2019 | — | −$8.13 | $0.08 | −$3.65 | — | — |
| 2020 | $0.35 | −$2.79 | $0.05 | −$2.17 | — | $3.41 |
| 2021 | $0.54 | −$2.29 | $0.05 | −$2.27 | — | $5.21 |
| 2022 | $0.14 | −$2.44 | $0.04 | −$2.20 | — | $3.82 |
| 2023 | $0.05 | −$1.59 | $0.01 | −$1.49 | — | $3.80 |
| 2024 | $1.29 | −$0.16 | $0.00 | −$0.04 | — | $4.50 |
| 2025 | $0.00 | −$1.18 | $0.01 | −$0.95 | — | $5.24 |
Common questions about Fulcrum Therapeutics
How much does one share of Fulcrum Therapeutics earn?
Over the last 12 months, Fulcrum Therapeutics lost $1.21 for each share.
Does Fulcrum Therapeutics pay a dividend?
Fulcrum Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Fulcrum Therapeutics’s book value per share?
Fulcrum Therapeutics’s book value is $4.07 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Fulcrum Therapeutics have?
Each share of Fulcrum Therapeutics has $0.64 of cash and investments, as of June 30, 2026.
What is Fulcrum Therapeutics’s free cash flow per share?
−$0.94 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Fulcrum Therapeutics bought back shares?
Fulcrum Therapeutics’s share count rose about 4940% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.